BHV Partners, a venture builder that specializes in creating disruptive start-ups in the health sector, has appointed entrepreneur Albert Mascarell as its new CEO, effective January 1, 2024.
Mascarell has more than 15 years of experience as founder and CEO of science start-ups like Plebiotic, Laboratorios BioInnove and aScidea, the latter two acquired by multinational pharmaceutical corporations. He also held positions of leadership at Fagron Genomics and the Fagron Group between 2018 and January 2023. Since 2015, he has been a start-up consultant accredited by ACCIÓ (Government of Catalonia), a mentor and professor at the UPF Barcelona School of Management, and an adviser to various start-ups and spinoffs.
Marta Príncep, Co-Founder and outgoing CEO of BHV Partners, said, “It has been a privilege to lead BHV Partners since it was established in 2019. Albert has extensive knowledge of how to create start-ups and drive their growth through to market, merger or acquisition, which will be of great value to BHV Partners as a venture builder and to the science and entrepreneurship community.”
Príncep will remain on the Board of Directors and will take charge of Director of Consultancy, a strategic business division for BHV Partners that requires an executive profile with broad experience in the sector.
Albert Mascarell said, “My passion and professional mission is to build and help others build their companies based on science and technology of excellence in order to address unmet medical needs. I’m happy to be joining BHV Partners as a partner and CEO because it is a benchmark venture builder in the healthcare ecosystem with an important plan for growth. There are exciting times ahead.”
Appointments to the Board of Directors
BHV Partners has expanded its Board of Directors, bringing Xavier Carbonell and Eva Berenguer on board in addition to Albert Mascarell. The knowledge of these experts will complement and bolster that of current board members Albert G. Zamora (chairman), Marta Príncep and Joaquim Trias.
Xavier Carbonell has been CEO of the Palex Group since 2007 and is a member of the Executive Board of the Spanish Federation of Healthcare Technology Companies (Fenin) and the Spanish Chamber of Commerce Innovation and Competitiveness Committee. He was previously head of Oncology at Amgen Spain and Medical Director and Head of Marketing for Novartis Oncology.
Eva Berenguer has been Chief Financial & Compliance Officer at SOM Biotech since 2022. Her more than 20 years in the business, mostly in the United States, have given her a proven record of success in organizational development, project management, corporate culture change, and internal and external auditing. She has previously held executive positions at Zimmer Biomet, Armacell, Robert Bosch Automotive Steering LLC and Baxter Healthcare.
“It is an honor to have Xavier and Eva on our Board of Directors. Their experience will be extremely valuable in making the most of BHV Partners’ potential,” noted Albert G. Zamora, chairman of the BHV Partners Board.